Grifols posted a 28.4 percent rise in net profit to 390 million euros for the first nine months of the year, the company announced Monday.
The Barcelona-based pharmaceutical group reported total revenue of 5,614 million euros between January and September, representing an increase of 4.6 percent at constant exchange rates, driven by sustained expansion in its core Biopharma division.

Adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) reached 1,392 million euros, marking a 5 percent increase compared with the same period a year earlier. The performance delivered an operating margin of 24.8 percent for the nine-month period, according to a regulatory statement submitted to the Spanish National Securities Market Commission (CNMV).
Debt reduction and financial leverage
The company reported further progress on lowering its debt burden, with its net leverage ratio dropping to 3.98 times EBITDA at the close of September.
The figure marks a steady improvement from 4.2 times recorded at the same point last year and 5.1 times posted two years ago. Grifols said in its regulatory filing that the continuing decline reflected ongoing efforts by the company to gradually scale down its overall indebtedness.
A company's net leverage ratio compares net debt against annual earnings before interest, tax, depreciation and amortisation, showing how many years of operating earnings would be needed to pay off debt obligations. Reducing the multiple has been a central operational target for the Spanish group as it seeks to strengthen its balance sheet and lower borrowing expenses.
Interim dividend and shareholder returns
Alongside its nine-month trading update, Grifols confirmed a direct financial return for its equity investors. The board of directors agreed to pay an interim dividend of 0.15 euros per share against financial results for the 2026 financial year.
The board approved the payout during a meeting held on Friday, prior to releasing the nine-month accounts to Spanish financial regulators at the start of the week.
An interim dividend allows a publicly traded company to distribute profits to shareholders before its full-year financial accounts are audited and concluded. The payment provides investors with an immediate cash return based on earnings generated during the first three quarters of the financial calendar.
Plasma therapies and global operations
Founded in Barcelona, Grifols is one of the world's leading manufacturers of plasma-derived medicines, producing specialized therapies used to treat rare, chronic, and life-threatening conditions.
The company's Biopharma division forms its largest business unit and serves as the primary engine of its revenue growth. The unit develops and sells essential biological treatments, including immunoglobulins to treat immune deficiencies and albumin used in hospital emergency care and surgical procedures.
These therapies are derived through a process known as plasma fractionation, in which donated human blood plasma is separated into distinct therapeutic proteins. The company operates a network of dedicated plasma donation centres across North America and Europe to maintain the steady biological supply required for its pharmaceutical manufacturing facilities.
Revenue growth was measured at constant exchange rates, an accounting standard that strips out the distorting effects of foreign exchange movements. The adjustment allows businesses with global operations to report underlying commercial performance across different currencies without fluctuations in currency markets obscuring operational gains.
Regulatory disclosure and market oversight
The quarterly results were communicated on Monday to the Comisión Nacional del Mercado de Valores, the state agency responsible for overseeing and inspecting financial markets across Spain.
The commission requires all publicly listed entities to submit financial statements and significant corporate events to ensure transparency for both domestic and international investors.
The latest filing confirms that Grifols enters the final quarter of 2026 with expanding core revenues and reduced financial leverage, maintaining its focus on disciplined balance sheet management.
